Literature DB >> 11584176

Idiopathic pulmonary fibrosis and malignancy.

Y Ma1, C K Seneviratne, M Koss.   

Abstract

The reported frequency of lung cancer in the setting of diffuse pulmonary fibrosis varies greatly, depending on the country of origin and the type of study. Most recent reports regarding diffuse pulmonary fibrosis in general and idiopathic pulmonary fibrosis in particular and lung cancers come from Japan; only a few clinical studies of this issue are available from other countries of the world, including the United States. The reported frequency ranges from 4.8% in the United States to 48.2% in Japan. The most frequent type of cancer is adenocarcinoma. Risk factors may include cigarette smoking, exposure to metal dusts, onset of idiopathic pulmonary fibrosis at an older age, and male predominance. Possible pathologic mechanisms are summarized. Given the very poor prognosis of idiopathic pulmonary fibrosis itself, with a mean survival of only 2.8 years, and that different diagnostic criteria were used in each study, it is likely that many of these studies are flawed because they evaluate lesions other than idiopathic pulmonary fibrosis. Thus, the frequency of lung cancer in idiopathic pulmonary fibrosis is still uncertain, and clearly requires follow-up of cohorts of clinically well-characterized patients, using standard diagnostic criteria for idiopathic pulmonary fibrosis. Finally, if the association between idiopathic pulmonary fibrosis and lung cancer is reconfirmed in these studies, the molecular and genetic mechanisms governing the development of lung cancer in this setting require additional study.

Entities:  

Mesh:

Year:  2001        PMID: 11584176     DOI: 10.1097/00063198-200109000-00005

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  11 in total

1.  Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Authors:  Masahiro Tsuboi; Thierry Le Chevalier
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 3.  Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.

Authors:  Beverley Forsythe; Karen Faulkner
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Risk of cancer in patients with scleroderma: a population based cohort study.

Authors:  C L Hill; A-M Nguyen; D Roder; P Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

Review 5.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

6.  Usual interstitial pneumonia with lung cancer: clinicopathological analysis of 43 cases.

Authors:  Dae Hyun Song; In Ho Choi; Sang Yun Ha; Kang Min Han; Jae Jun Lee; Min Eui Hong; Kyeongman Jeon; Man Pyo Chung; Jhingook Kim; Joungho Han
Journal:  Korean J Pathol       Date:  2014-02-25

Review 7.  Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?

Authors:  Argyris Tzouvelekis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2006-05-25

8.  Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation.

Authors:  L E L Hendriks; M Drent; E H J van Haren; J A Verschakelen; G M Verleden
Journal:  Respir Med Case Rep       Date:  2012-03-17

Review 9.  The epidemiology of interstitial lung disease and its association with lung cancer.

Authors:  G Raghu; F Nyberg; G Morgan
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

10.  Prevalence, risk factors, and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis: a study from the Middle East.

Authors:  Sherif Mohamed; Hassan Bayoumi; Nashwa Abd El-Aziz; Ehab Mousa; Yasser Gamal
Journal:  Multidiscip Respir Med       Date:  2018-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.